Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01980628 · ClinicalTrials.gov registry record · Phase 2
Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed/Refractory Marginal Zone Lymphoma
A Phase 2 study of Marginal Zone Lymphoma and B-cell Lymphoma, sponsored by Pharmacyclics.
- Completed
- Registry status
- Phase 2
- Development phase
- 63
- Enrollment target
- 20
- Study locations
NCT01980628 is a Phase 2 study of Marginal Zone Lymphoma and B-cell Lymphoma that has completed, run by Pharmacyclics. The registered enrollment target is 63 participants, below the 101-participant average among 49 other Marginal Zone Lymphoma trials with a reported enrollment target (38% lower). The trial reports 20 study locations across 15 states.
The verdict
NCT01980628, a Phase 2 study of Marginal Zone Lymphoma and B-cell Lymphoma, has completed, sponsored by Pharmacyclics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 63 participants
- Enrollment target
- 20
- Study locations
Study Summary
Phase 2, open-label, non-randomized, monotherapy study to evaluate the safety and efficacy of ibrutinib in subject with relapsed/refractory Marginal Zone Lymphoma (MZL).
Conditions Studied
Interventions
- DRUG ibrutinib
Study Locations (20)
New York
- Site Reference ID/Investigator# 350 - New Hyde Park
- Site Reference ID/Investigator# 745 - New York
- Site Reference ID/Investigator # 200 - New York
- Site Reference ID/Investigator # 407 - New York
California
- Site Reference ID/Investigator# 047 - Duarte
- Site Reference ID/Investigator# 377 - Santa Monica
Pays de la Loire Region
- Site Reference ID/Investigator# 749 - La Roche-sur-Yon
- Site Reference ID/Investigator# 736 - Nantes
Arizona
- Site Reference ID/Investigator# 837 - Tucson
Florida
- Site Reference ID/Investigator# 763 - West Palm Beach
Georgia
- Site Reference ID/Investigator# 033 - Atlanta
Illinois
- Site Reference ID/Investigator# 370 - Chicago
Michigan
- Site Reference ID/Investigator# 195 - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2013-12 |
| Est. Completion | 2017-10-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01980628
The ClinicalTrials.gov registry entry for NCT01980628 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 63 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 101-participant average among 49 other Marginal Zone Lymphoma trials with a reported enrollment target (38% lower). The listed sponsor is Pharmacyclics, which has 54 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Marginal Zone Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which ibrutinib is the first listed.
NCT01980628 reports 20 study locations spanning 15 distinct geographic areas - top geographies include New York, California, Pays de la Loire Region.
Frequently Asked Questions
What is clinical trial NCT01980628 about?
NCT01980628 is a clinical study titled "Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed/Refractory Marginal Zone Lymphoma". Phase 2, open-label, non-randomized, monotherapy study to evaluate the safety and efficacy of ibrutinib in subject with relapsed/refractory Marginal Zone Lymphoma (MZL).
What is the current status of trial NCT01980628?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 63 participants. The study started on 2013-12. Estimated completion is 2017-10-02.
What conditions does trial NCT01980628 study?
This clinical trial studies the following conditions: Marginal Zone Lymphoma, B-cell Lymphoma.
What interventions are being tested in trial NCT01980628?
The interventions under investigation include: ibrutinib (DRUG).
Who is sponsoring clinical trial NCT01980628?
This trial is sponsored by Pharmacyclics, which has 54 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01980628 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Marginal Zone Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas
RECRUITING · Phase 2
-
Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL)
RECRUITING · Phase 2
-
Open-label of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Marginal Zone Lymphoma
RECRUITING · Phase 2
-
HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL
RECRUITING · Phase 2
-
Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma
RECRUITING · Phase 2
-
Pirtobrutinib in Combination With Rituximab in Adults With Untreated Marginal Zone Lymphoma (PIONEER-MZL)
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.